Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma

Transfusion

Volumn 48, Issue 12, 2008, Pages 2624-2628

  Kiefer, Thomas ^b   Krüger, William H ^a   Montemurro, Michael ^b   Schüler, Frank ^b   Hirt, Carsten ^b   Pasold, Rita ^b   Niederwieser, Dietger ^b   Schwenke, Matthias ^b   Dölken, Gottfried ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FOLINIC ACID; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CD34 SELECTION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HEMATOPOIESIS; HUMAN; LEUKAPHERESIS; MALE; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED;

EID: 57249086394     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01927.x     Document Type: Article

References (13)

1. Deangelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002 20 : 4643 8.
2. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003 21 : 4151 6.
3. Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russell JA, Stewart DA. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003 31 : 679 85.
4. Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broet S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006 38 : 417 20.
5. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006 24 : 3865 70.
6. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001 19 : 742 9.
7. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000 11 : 927 37.
8. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003 21 : 2407 14.
9. Herrlinger U, Korfel A, Hebart H, Schlegel U, Plasswilm L, Illerhaus G, Finke J, Krüger W, Montemurro M, Wolf T, Thiel E, Bamberg M, Weller M, Kanz L. Meeting report: primary central nervous system lymphoma: standards of care and future perspectives. Onkologie 2005 28 : 109 11.
10. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, Thiel E. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005 16 : 445 9.
11. Montemurro M, Kiefer T, Schuler F, Al-Ali H, Wolf HH, Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Krüger W, Dölken G. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007 18 : 665 71.
12. Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001 27 : 463 70.
13. Kroger N, Renges H, Sonnenberg S, Krüger W, Gutensohn K, Dielschneider T, Cortes-Dericks L, Zander AR. Stem cell mobilisation with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002 29 : 727 30.